SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neopath (NPTH)
NPTH 0.0006000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sigmund who wrote (83)12/30/1997 5:48:00 PM
From: Frank Buck  Read Replies (1) of 178
 
Sigmund,

I will agree that there is a definite fine line when it comes to the FDA. One only has to look at the recent heart problems associated with the phen-phen class of FDA approved drugs to realize that the FDA does occasionally let some flyers pass. And that is with a series of three FDA clinical trials. Something that the medical-device manufacturers don't have to provide.

This morning as I was reading the Journal, I came across an article of a drug, Seldane that was being pulled from the shelves because of related deaths from it. Here is a drug that has been on the market for maybe ten-years. I know because I took it for an occasional annual spring allergy problem. Now I hear that a combination of grapefruit juice and Seldane could have killed me-wow! Good thing I don't live
in California or Florida where my beverage of washing down pills
might have been grapefruit juice.

Progress is good as long as it is tempered with restraint and attention to the associated peripheral details.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News